Needham & Company LLC Cuts Cooper Companies (NASDAQ:COO) Price Target to $73.00

Cooper Companies (NASDAQ:COO) had its price target cut by equities research analysts at Needham & Company LLC from $86.00 to $73.00 in a report issued on Thursday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price target would indicate a potential upside of 15.00% from the stock’s previous close.

A number of other research analysts also recently weighed in on the stock. Wells Fargo & Company reissued a “sell” rating and set a $66.00 target price (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. Stifel Nicolaus lowered their price target on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, June 5th. The Goldman Sachs Group set a $61.00 price objective on Cooper Companies in a research note on Wednesday, May 27th. Mizuho set a $85.00 price objective on Cooper Companies and gave the company an “outperform” rating in a report on Thursday, June 4th. Finally, BNP Paribas Exane decreased their target price on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $75.27.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $63.48 on Thursday. The company’s 50-day moving average is $72.42 and its 200 day moving average is $70.02. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The company has a market capitalization of $12.38 billion, a P/E ratio of 53.80, a price-to-earnings-growth ratio of 1.77 and a beta of 0.82. Cooper Companies has a fifty-two week low of $58.89 and a fifty-two week high of $89.83.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the business earned $0.49 earnings per share. The firm’s revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities research analysts forecast that Cooper Companies will post 4.63 earnings per share for the current year.

Cooper Companies announced that its board has initiated a share repurchase plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Institutional Trading of Cooper Companies

A number of hedge funds and other institutional investors have recently bought and sold shares of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock worth $1,890,000 after purchasing an additional 7,363 shares during the period. First Trust Advisors LP grew its position in Cooper Companies by 115.8% during the second quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock valued at $9,702,000 after acquiring an additional 73,165 shares during the last quarter. Cresset Asset Management LLC purchased a new stake in shares of Cooper Companies in the 2nd quarter valued at $291,000. Cerity Partners LLC boosted its position in Cooper Companies by 4.4% during the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock valued at $1,272,000 after buying an additional 757 shares during the period. Finally, Daiwa Securities Group Inc. boosted its holdings in Cooper Companies by 2.8% during the 2nd quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock valued at $2,551,000 after acquiring an additional 973 shares during the period. Institutional investors own 24.39% of the company’s stock.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal third-quarter adjusted EPS of $1.15, ahead of the $1.11–$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. Management also repurchased $339.1 million of stock during the quarter, supporting per-share value if executed effectively. CooperCompanies Completes Strategic Review
• Neutral Sentiment: GAAP EPS was $2.24, helped substantially by a $307.2 million discrete tax benefit related to the favorable completion of a U.K. tax examination. This benefit improves reported results but is not representative of recurring operating performance. CooperCompanies Reports Third-Quarter Results
• Negative Sentiment: CooperCompanies lowered fiscal 2026 adjusted EPS guidance to $4.51–$4.55, below the roughly $4.63 consensus, and set fourth-quarter EPS guidance at $1.05–$1.09 versus expectations near $1.20. Full-year revenue guidance of $4.229–$4.252 billion also implies modest growth.
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because potential offers were not sufficiently attractive. Investors appear disappointed that the company did not unlock value through a sale, particularly amid fertility-related litigation costs and competitive pressure in the IUD market. Reasons Cooper Companies Stock Is Under Pressure

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.